All authors have seen and approved the manuscript. Work for this study was performed at Royal North Shore Hospital, Sydney and Charles Perkins Centre, University of Sydney. Funding for the original manuscript: A.M.M. received research grants from the following: Ramsay Research and Teaching Fund, Sydney, Australia, and a ResMed Foundation/Sleep Health Foundation Research Entry Scholarship administered through the Royal Australasian College of Physicians, Sydney, Australia. A.M.M. reports that in-kind support for this study (loan of ApneaLink Air diagnostic study devices) was received from ResMed Pty Ltd., Sydney, Australia. ResMed played no role in the design or implementation of the study. P.A.C. has an appointment to an endowed academic chair at the University of Sydney that was created from ResMed funding. He receives no personal fees and this relationship is managed by an oversight committee of the university. He has received research support from ResMed, SomnoMed, Zephyr Sleep Technologies, and Bayer. He is a consultant/adviser to Zephyr Sleep Technologies, ResMed, SomnoMed, and Signifier Medical Technologies. He has a pecuniary interest in SomnoMed related to a previous role in R&D (2004). K.S. reports in-kind support from SomnoMed in donation of oral appliances for a previous investigator-initiated research study. The trial discussed in this letter was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR): 12616001016426.